XNCR News and Press, Xencor Inc. From 12/11/19

Shares of Stemline Therapeutics ( STML ) have lost a third of their value since my August article recommended buying shares given the fact that the Q2 report showed progress on multiple fronts. Recently, at the ASH (American Society of Hematology) annual meeting, the company unveiled prom...

-- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced initial dat...

The following slide deck was published by Xencor, Inc. in conjunction with this Read more ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb ® 1...

Xencor, Inc. (XNCR) Q3 2019 Earnings Conference Call November 05, 2019 04:30 PM ET Company Participants Charles Liles - Associate Director and Head, Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer John Kuch - Senior Vice ...

Xencor (NASDAQ: XNCR ): Q3 GAAP EPS of -$0.18 beats by $0.37 . More news on: Xencor, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Management to Host Conference Call at 4:30 p.m. ET today -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial re...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release third quarter 2019 financial results after the market closes...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will present at the 2019 Cantor Global Healthcare Conferen...

School is back in session, football season is under way, and the post-Labor Day IPO market has provided new investment opportunities, with some shining stocks debuting in the healthcare sector.  Last week, three healthcare companies completed their IPOs: 10X Genomics (NASDAQ: TXG) , ...